Tag archive for ‘Copaxone’
Shai Genish On Thursday, October 26th, 2017

The UK Court Overturned Teva’s Copaxone Patent

Facebook1 Twitter Google Plus0 Pinterest0 Email   The British Supreme Court ruled Thursday in favor of Mylan and its Dutch partner Synthon, and canceled all Teva’s Copaxone for 40 mg in the country based More...

Teva Receives Approval to Market Copaxone in Japan

Facebook0 Twitter Google Plus0 Pinterest0 Email   Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) announced today that the the Japanese Ministry of Health, Labour and Welfare has approved More...

Niva Goldberg On Tuesday, July 7th, 2015

Three Way Takeover Battle: Teva Plans Raising Mylan Bid to $43 Billion – Report

Facebook0 Twitter Google Plus0 Pinterest0 Email Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), the Israeli drugmaker, is preparing to improved proposal for US rival Mylan to as much as $43 More...

Niva Goldberg On Thursday, June 18th, 2015

U.S. Court Invalidates Teva’s Copaxone Patent

Facebook0 Twitter Google Plus0 Pinterest0 Email The U.S. Court of Appeals has again ruled that Teva Pharmaceuticals Industries Ltd.’s patent for its top-selling multiple sclerosis treatment Copaxone is invalid. A More...

Ilan Shavit On Monday, March 30th, 2015

Teva Buying Auspex for $3.5 Billion in Anticipation of Competition Over Copaxone

Facebook0 Twitter Google Plus0 Pinterest0 Email Read also: CEO Vigodman In Race To Save Teva Through ‘Inorganic Growth’ Just as JBN predicted (along with everybody else in the business) Teva Pharmaceutical More...

Shiri Habib-Valdhorn On Tuesday, January 27th, 2015

Teva Rivals Urge US Court to Expedite Copaxone Suit

Facebook0 Twitter Google Plus0 Pinterest0 Email Copaxone’s patent remains in force at least until the Federal Circuit Appeals Court reconsiders the case. The rivals of Teva Pharmaceutical Industries Ltd. More...

Globes On Monday, January 26th, 2015

Teva Gets First “Sell” Recommendation

Facebook0 Twitter Google Plus0 Pinterest0 Email Berenberg analysts see insurance companies pressuring MS patients to switch to generic versions of Copaxone. Last year, Teva Pharmaceutical Industries Ltd. (NYSE: More...

Nadav Neuman On Wednesday, January 21st, 2015

US Supreme Court Upholds Copaxone Patent

Facebook0 Twitter Google Plus0 Pinterest0 Email The ruling means Teva’s flagship multiple sclerosis treatment’s patent remains valid until September 2015.   The US Supreme Court has ruled in More...

OPKO
Shiri Habib-Valdhorn On Thursday, December 18th, 2014

Teva and Russian Partner at Loggerheads

Facebook0 Twitter Google Plus0 Pinterest0 Email – Relations between Teva and Biotec have deteriorated into a legal dispute and an entanglement with the Russian authorities. –   After years of More...

Gil Tanenbaum On Wednesday, December 17th, 2014

Israeli Bio Med Firm Mapi Pharma Makes Headway in MS Medication

Facebook0 Twitter Google Plus0 Pinterest0 Email Israeli biomed firm Mapi Pharma Ltd., which is a development stage pharmaceutical company, announced that the first patient was treated in the company’s More...

Email:

Delivered by FeedBurner